Products for Research Use Only

Inotuzumab ozogamicin

CAT: 0804-HY-P9959Size: 1 EachDry Ice: YesHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-P9959Size:1 Each
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Inotuzumab ozogamicin (CMC-544) is an anti-CD22 antibody-drug conjugate (ADC). Inotuzumab ozogamicin consists of a humanized IgG4 anti-CD22 mAb, covalently linked to Calicheamicin via an acid-labile AcBut (HY-132261) linker. The antibody portion is Inotuzumab (HY-P99264), and the drug-linker conjugate for ADC is N-Ac-γ-Calicheamicin-AcBut-NHS ester (HY-103688). Inotuzumab ozogamicin binds to the minor groove of DNA, inducing double-strand cleavage and subsequent apoptosis. Inotuzumab ozogamicin can be used for the study of relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).
CAS Number
635715-01-4
Product Name Alternative
CMC-544; PF-5208773; WAY-207294
UNSPSC
12352203
Target
Antibody-Drug Conjugates (ADCs) ; Apoptosis; CD22; DNA/RNA Synthesis
Related Pathways
Antibody-drug Conjugate/ADC Related; Apoptosis; Cell Cycle/DNA Damage; Immunology/Inflammation
Applications
Cancer-programmed cell death
Field of Research
Cancer
Solubility
H2O
Smiles
[Inotuzumabozogamicin]
References & Citations
[1]Bruzzese A, et al. Therapeutic Strategies for Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia in Adult Patients: Optimizing the Use of Monoclonal Antibodies. Eur J Haematol. 2025 Jun;114 (6) :938-952.
Shipping Conditions
Dry Ice
Scientific Category
Inhibitory Antibodies
Clinical Information
Launched